- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Kodak names Jackman CTO
Michael W. Jackman has been named chief technology officer and a divisional vice president for Kodak's Health Imaging Group. He will lead Health Imaging's global R&D operation with a strategic focus on delivering new technology, products, and services by
Michael W. Jackman has been named chief technology officer and a divisional vice president for Kodak's Health Imaging Group. He will lead Health Imaging's global R&D operation with a strategic focus on delivering new technology, products, and services by leveraging intellectual property and technology investments, according to the company. Jackman will also steer the design, development, and expansion of Health Imaging's digital product portfolio. Jackman was founder and CEO of a consulting firm specializing in technology development and strategy for companies in the wireless, IP telephony, security, and software infrastructure areas. He has held top marketing, sales, and development positions at various technology companies including IBM. Health Imaging is Kodak's second-largest business, with annual revenue of more than $2.3 billion.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
